QPPV.COM KNOWLEDGE ASSESSMENT

Professional Knowledge Assessment: Tildrakizumab Pharmacovigilance

Test your understanding of the concepts covered by Tildrakizumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which description best captures the pharmacological identity of tildrakizumab?

A small-molecule inhibitor that blocks multiple intracellular kinases A humanised IgG1κ monoclonal antibody that selectively binds the IL-23 p19 subunit A chimeric antibody that directly neutralises tumour necrosis factor A recombinant enzyme replacement administered by intravenous infusion

Question 2 of 10 Which exposure information is especially important because tildrakizumab is used at extended maintenance intervals?

Only the patient's date of birth Whether the patient received any medicine in the previous year Exact dose dates, treatment phase and any delayed or missed doses Only the date on which the adverse event was reported

Question 3 of 10 What is the main limitation of relying only on preferred-term counts in signal detection?

Preferred terms cannot be used in pharmacovigilance Several terms may represent one syndrome, while one term may combine different mechanisms Preferred terms always overestimate the number of exposed patients Preferred terms automatically establish clinical seriousness

Question 4 of 10 Which finding would most strongly weaken an initial hypothesis that a new symptom was caused by tildrakizumab?

The symptom began after exposure The event has a plausible biological mechanism A well-documented alternative diagnosis explains the phenotype and objective findings better The patient has plaque psoriasis

Question 5 of 10 Which statement best expresses the article's approach to mechanism-led pharmacovigilance?

Mechanism alone is sufficient to assign causality Mechanism should guide the phenotype and follow-up sought, while clinical evidence and alternatives determine interpretation Mechanism is useful only during preclinical development Mechanism should be ignored because all adverse events are nonspecific

Question 6 of 10 Which conclusion is most appropriate after identifying an increased reporting pattern for a possible tildrakizumab-associated event?

The pattern proves a causal relationship The pattern is irrelevant unless every case is medically confirmed The pattern is a signal hypothesis requiring further evaluation The pattern should be removed if the event is also associated with the underlying disease

Question 7 of 10 What does a high-quality follow-up process measure according to the article?

Whether a follow-up request was sent, regardless of the outcome Whether relevant information was obtained, evaluated and incorporated into the case The number of standard questionnaires issued per case Whether the reporter used the preferred terminology

Question 8 of 10 Which pharmacovigilance implication follows most directly from subcutaneous administration?

Only systemic infections need to be assessed Administration timing, injection-site reactions, technique and batch traceability become relevant The product cannot produce immunogenicity Dose chronology is less important than for oral medicines

Question 9 of 10 Which combination best reflects the three interacting layers of tildrakizumab safety assessment?

Product price, prescriber preference and dispensing location Direct pharmacology, host susceptibility and the treatment environment Clinical trial size, packaging design and marketing status Disease terminology, reporter identity and reporting date

Question 10 of 10 Which set of fields would most directly support inspection-ready traceability from an individual case to regulatory decision-making?

Only the final causality category and reporter specialty Source information, exposure and product details, medical assessment, follow-up, aggregate review and documented decisions Only the product name and date of case closure A list of standard operating procedures without evidence of their use

QPPV.com

Professional Knowledge Assessment: Tildrakizumab Pharmacovigilance

Cookie Settings